ArticleOncoTargets and therapy2017
The clinical significance of CXCL5 in non-small cell lung cancer.
Article in OncoTargets and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 46 citations in OpenAlex.
- Novel Blood-Based Extracellular Vesicle-Derived Biomarkers in Small Cell Lung Cancer Identified via Proximity Extension Assay.Cancers · 2026Article
- Chemokines: humble yet mighty players in the tumour microenvironment.Frontiers in immunology · 2025Review
- Study of the Expression of Pain and Inflammation Pathway Genes and Their Associated miRNAs in Patients With Endometriosis.BioMed research international · 2025Article
- Relationships of emerging biomarkers of cancer cachexia with quality of life, appetite, and cachexia.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- MDA-9/Syntenin in the tumor and microenvironment defines prostate cancer bone metastasis.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Article
- Targeting CXCL5 in Pancreatic Cancer Cells Inhibits Cancer Xenograft Growth by Reducing Proliferation and Inhibiting EMT Progression.Digestive diseases and sciences · 2023Article
- The Role of CXC Chemokines in Cancer Progression.Cancers · 2022Review
- Epigenetic alterations of CXCL5 in Cr(VI)-induced carcinogenesis.The Science of the total environment · 2022Article
- Genomically Silent Refractory Gastric Cancer in a Young Patient Exhibits Overexpression of CXCL5.Current oncology (Toronto, Ont.) · 2022Article
- Identification of CXCL5 expression as a predictive biomarker associated with response and prognosis of immunotherapy in patients with non-small cell lung cancer.Cancer medicine · 2022Article
- CXCL5-mediated accumulation of mature neutrophils in lung cancer tissues impairs the differentiation program of anticancer CD8 T cells and limits the efficacy of checkpoint inhibitors.Oncoimmunology · 2022Article
- Identification of the dominant angiogenic CXCL class chemokines associated with non-small cell lung cancer via bioinformatics tools.Medical oncology (Northwood, London, England) · 2021Article
- Bioinformatics Analysis of Differentially Expressed Genes and Protein-Protein Interaction Networks Associated with Functional Pathways in Ulcerative Colitis.Medical science monitor : international medical journal of experimental and clinical research · 2021Article
- CXCL5 expression in tumor tissues is associated with poor prognosis in patients with pancreatic cancer.Oncology letters · 2020Article
- Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook.Molecular cancer · 2020Review
- Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer andWorld journal of gastroenterology · 2020Article
- CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target.Cancer communications (London, England) · 2020Review
- Identification of 10 Hub genes related to the progression of colorectal cancer by co-expression analysis.PeerJ · 2020Article
- CXCL5 overexpression predicts a poor prognosis in pancreatic ductal adenocarcinoma and is correlated with immune cell infiltration.Journal of Cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a CXC-type chemokine, ENA78/CXCL5 is an important attractant for granulocytes by binding to its receptor CXCR2. Recent studies proved that CXCL5/CXCR2 axis plays an oncogenic role in many human cancers. However, the exact clinical significance of CXCL5 in lung cancer has not been well defined. Here, we found that the serum protein expression of CXCL5 was significantly increased in non-small cell lung cancer (NSCLC) compared with that in healthy volunteers. Immunohistochemistry staining revealed that CXCL5 protein was higher in various lung cancer tissues compared with normal tissues. Moreover, CXCL5 expression correlated with histological grade, tumor size, and TNM stage in NSCLC. Elevated CXCL5 protein abundance predicted poor overall survival in adenocarcinoma patients. Further meta-analysis demonstrated that CXCL5 mRNA expression was also positively associated with tumor stage, lymph node metastasis, and worse survival. Kaplan-Meier plot analyses indicated high CXCL5 was associated with short overall survival and progression-free survival. Together, these results indicated that CXCL5 may be a potential biomarker for NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.